Marzia Varettoni

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1102793/publications.pdf

Version: 2024-02-01

158 papers	5,017 citations	117453 34 h-index	98622 67 g-index
158 all docs	158 docs citations	158 times ranked	5544 citing authors

#	Article	IF	Citations
1	Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology, 2010, 21, 325-330.	0.6	386
2	MYD88 L265P in WaldenstrÃ¶m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood, 2013, 121, 2051-2058.	0.6	368
3	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in WaldenstrÃ¶mâ€™s macroglobulinemia and related lymphoid neoplasms. Blood, 2013, 121, 2522-2528.	0.6	290
4	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. New England Journal of Medicine, 2015, 373, 1733-1747.	13.9	281
5	Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica, 2008, 93, 1645-1651.	1.7	241
6	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 2020, 34, 2354-2363.	3.3	198
7	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood, 2012, 119, 188-191.	0.6	150
8	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Annals of Oncology, 2014, 25, 1404-1410.	0.6	133
9	Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. Bone Marrow Transplantation, 1999, 23, 533-537.	1.3	130
10	Clonal architecture of <scp>CXCR</scp>4 <scp>WHIM</scp>â€like mutations in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 172, 735-744.	1.2	122
11	A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia, 2007, 21, 1545-1548.	3.3	98
12	Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia. Cancer, 2012, 118, 434-443.	2.0	97
13	Consensus treatment recommendations from the tenth International Workshop for WaldenstrÃ¶m Macroglobulinaemia. Lancet Haematology,the, 2020, 7, e827-e837.	2.2	96
14	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica, 2010, 95, 1792-1796.	1.7	91
15	Pattern of somatic mutations in patients with WaldenstrÃ¶m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica, 2017, 102, 2077-2085.	1.7	90
16	Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clinical Neurophysiology, 2008, 119, 2507-2512.	0.7	88
17	Central nervous system involvement by WaldenstrÃ¶m macroglobulinaemia (Bingâ€Neel syndrome): a multiâ€institutional retrospective study. British Journal of Haematology, 2016, 172, 709-715.	1.2	87
18	Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients. Leukemia Research, 2010, 34, 471-474.	0.4	75

#	Article	IF	Citations
19	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica, 2015, 100, 246-252.	1.7	73
20	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood, 2019, 133, 299-305.	0.6	69
21	Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Annals of Hematology, 2004, 83, 588-91.	0.8	64
22	Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplantation, 2000, 25, 309-313.	1.3	63
23	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for WaldenstrÃ¶m's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. Journal of Clinical Oncology, 2022, 40, 52-62.	0.8	62
24	Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma. Cancer, 2005, 104, 118-125.	2.0	61
25	Recommendations for the diagnosis and initial evaluation of patients with WaldenstrÃ¶m Macroglobulinaemia: A Task Force from the 8th International Workshop on WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 175, 77-86.	1.2	61
26	Zanubrutinib for the treatment of MYD88 wild-type WaldenstrÃ¶m macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Advances, 2020, 4, 6009-6018.	2.5	57
27	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	3.3	57
28	MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood, 2013, 122, 2284-2285.	0.6	56
29	Bendamustine and rituximab combination is safe and effective as salvage regimen in WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2015, 56, 2637-2642.	0.6	55
30	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. Blood, 2019, 134, 798-801.	0.6	53
31	A revised international prognostic score system for WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia, 2019, 33, 2654-2661.	3.3	53
32	Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. Leukemia, 2004, 18, 1512-1517.	3.3	50
33	Risk of second cancers in WaldenstrÃ¶m macroglobulinemia. Annals of Oncology, 2012, 23, 411-415.	0.6	50
34	Rapid Response to High-Dose Steroids of Severe Bortezomib-Related Pulmonary Complication in Multiple Myeloma. Journal of Clinical Oncology, 2007, 25, 3380-3381.	0.8	36
35	The possible role of burden of therapy on the risk of myeloma extramedullary spread. Annals of Hematology, 2017, 96, 73-80.	0.8	34
36	CD38, BCLâ€2, PDâ€1, and PDâ€1L expression in nodal peripheral Tâ€cell lymphoma: Possible biomarkers for novel targeted therapies?. American Journal of Hematology, 2017, 92, E1-E2.	2.0	33

#	Article	IF	Citations
37	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood, 2020, 136, 763-766.	0.6	33
38	Clues to the Pathogenesis of Waldenstrol̀m Macroglobulinemia and Other Monoclonal IgM Disorders Provided by the Analysis of Immunoglobulin Heavy Chain Gene Rearrangement and Clustering of B-Cell Receptors,. Blood, 2011, 118, 3680-3680.	0.6	33
39	Clues to pathogenesis of WaldenstrÃ¶m macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. Leukemia and Lymphoma, 2013, 54, 2485-2489.	0.6	31
40	Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells, Molecules, and Diseases, 2009, 42, 286-291.	0.6	30
41	Assessment of bone marrow involvement in nonâ€Hodgkinâ€™s lymphomas: comparison between histology and flow cytometry. European Journal of Haematology, 2010, 85, 405-415.	1.1	30
42	MYD88 mutated and wild-type WaldenstrÃ¶mâ€™s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica, 2018, 103, e408-e411.	1.7	30
43	Emergent Tâ€helper 2 profile with high interleukinâ€6 levels correlates with the appearance of bortezomibâ€induced neuropathic pain. British Journal of Haematology, 2010, 149, 916-918.	1.2	28
44	Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. Blood, 2020, 135, 293-296.	0.6	27
45	Clinical Characteristics and Outcome of Immunoglobulin Mâ€“Related Disorders. Clinical Lymphoma and Myeloma, 2005, 5, 261-264.	2.1	26
46	Monoclonal gammopathy of undetermined significance: a new proposal of workup. European Journal of Haematology, 2013, 91, 356-360.	1.1	24
47	Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 231-234.	0.2	24
48	Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma. Hematological Oncology, 2017, 35, 296-302.	0.8	23
49	Distinctive Clinical and Histological Features of WaldenstrÃ¶m's Macroglobulinemia and Splenic Marginal Zone Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 103-105.	0.2	22
50	Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy. Seminars in Oncology, 2003, 30, 172-177.	0.8	21
51	Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Leukemia and Lymphoma, 2010, 51, 236-242.	0.6	19
52	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. American Journal of Hematology, 2019, 94, 1193-1199.	2.0	18
53	Bing-Neel Syndrome: illustrative cases and comprehensive review of the literature. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017061.	0.5	17
54	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. British Journal of Haematology, 2020, 190, 901-908.	1.2	17

#	Article	IF	Citations
55	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. Leukemia, 2021, 35, 235-238.	3.3	17
56	Normal-looking skin in oncohaematological patients after allogenic bone marrow transplantation is not normal. British Journal of Dermatology, 2004, 151, 579-586.	1.4	16
57	Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance. Medicine (United States), 2010, 89, 211-216.	0.4	16
58	Successful treatment with <scp>R</scp>ituximab and <scp>B</scp>endamustine in a patient with newly diagnosed <scp>W</scp>aldenstrÃ¶m's <scp>M</scp>acroglobulinemia complicated by <scp>B</scp>ingâ€“<scp>N</scp>eel syndrome. American Journal of Hematology, 2015, 90, E152-3.	2.0	16
59	Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial. Blood, 2020, 136, 29-30.	0.6	16
60	Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are shortâ€lived. European Journal of Haematology, 2009, 83, 449-454.	1.1	15
61	Associated Cancers in WaldenstrÃ¶m Macroglobulinemia: Clues for Common Genetic Predisposition. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 700-703.	0.2	15
62	Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. Hematological Oncology, 2019, 37, 160-167.	0.8	15
63	Diagnostic framing of IgM monoclonal gammopathy: Focus on WaldenstrÃ¶m macroglobulinemia. Hematological Oncology, 2019, 37, 117-128.	0.8	15
64	MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. Diagnostics, 2021, 11, 779.	1.3	14
65	A riskâ€stratification model based on the initial concentration of the serum monoclonal protein and <scp>MYD</scp>88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to WaldenstrÃ¶m macroglobulinaemia or other lymphoproliferative disorders. British Journal of Haematology, 2019, 187, 441-446.	1.2	13
66	Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma. Oncology, 2005, 68, 146-153.	0.9	12
67	Prognostic Factors for Transformation in Asymptomatic Immunoglobulin M Monoclonal Gammopathies. Clinical Lymphoma and Myeloma, 2005, 5, 265-269.	2.1	12
68	DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion, 2008, 48, 857-860.	0.8	11
69	Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. Leukemia Research, 2009, 33, e145-e149.	0.4	11
70	Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 77-79.	0.2	11
71	The Impact of Advanced Age According to IPSSWM Cut-Off on the Outcome of Symptomatic and Asymptomatic WaldenstrÃ¶m's Macroglobulinemia at Diagnosis. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 124-126.	0.2	11
72	Consensus Statement on the Management of WaldenstrÃ¶m Macroglobulinemia Patients During the COVIDâ€19ÂPandemic. HemaSphere, 2020, 4, e433.	1.2	11

#	Article	IF	Citations
73	Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. Leukemia, 2004, 18, 1555-1557.	3.3	10
74	Changes in multiple myeloma epidemiology in the last thirty years: A single centre experience. European Journal of Cancer, 2006, 42, 396-402.	1.3	10
75	Microarray Demonstrates Different Gene Expression Profiling Signatures Between WaldenstrÃ¶m Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 208-210.	0.2	10
76	Assessment of the 4â€factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American Journal of Hematology, 2021, 96, E168-E171.	2.0	10
77	Flexural erythematous eruption following autologous peripheral blood stem cell transplantation: a study of four cases.. British Journal of Dermatology, 2001, 145, 490-495.	1.4	9
78	Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplantation, 2004, 34, 1039-1045.	1.3	9
79	Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow Transplantation, 2005, 36, 951-954.	1.3	9
80	Thrombomodulin levels are not modified during thalidomide treatment. European Journal of Haematology, 2006, 77, 453-454.	1.1	9
81	Late onset of bortezomib-associated cutaneous reaction following herpes zoster. Annals of Hematology, 2007, 86, 301-302.	0.8	9
82	Infiltration of the Spinal Cord in a Patient With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 4207-4209.	0.8	9
83	Autologous stem cell transplantation with in vivo purged progenitor cells shows longâ€term efficacy in relapsed/refractory follicular lymphoma. American Journal of Hematology, 2015, 90, 230-234.	2.0	9
84	Bone marrow assessment in asymptomatic immunoglobulin <scp>M</scp> monoclonal gammopathies. British Journal of Haematology, 2015, 168, 301-302.	1.2	9
85	Management of chronic lymphocytic leukemia in Italy during a one year of the COVIDâ€19 pandemic and at the start of the vaccination program. A Campus CLL report. Hematological Oncology, 2021, 39, 570-574.	0.8	9
86	Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome. Blood, 2018, 132, 2026-2026.	0.6	9
87	Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. Annals of Hematology, 2001, 80, 521-524.	0.8	8
88	Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas. Leukemia Research, 2008, 32, 841-843.	0.4	8
89	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. Hematological Oncology, 2021, 39, 326-335.	0.8	8
90	<scp>TP53</scp> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 2021, 96, E306-E310.	2.0	8

#	Article	IF	Citations
91	Bortezomib with HIG-Dose Dexamethasone as First Line Therapy in Patients with Multiple Myeloma Candidates to High-Dose Therapy.. Blood, 2007, 110, 3595-3595.	0.6	8
92	Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. Blood Cancer Journal, 2022, 12, .	2.8	8
93	Severe intestinal vasculitis in a patient under treatment with bortezomib. Annals of Hematology, 2007, 86, 923-924.	0.8	7
94	Targeted nextâ€generation sequencing reveals molecular heterogeneity in nonâ€chronic lymphocytic leukemia clonal Bâ€cell lymphocytosis. Hematological Oncology, 2020, 38, 689-697.	0.8	7
95	Younger patients with WaldenstrÃ¶m Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. American Journal of Hematology, 2020, 95, 1473-1478.	2.0	7
96	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisibâ€“rituximab. Blood Cancer Journal, 2020, 10, 92.	2.8	7
97	Mutational and immunogenetic landscape of <scp>HCV</scp>â€associated Bâ€cell lymphoproliferative disorders. American Journal of Hematology, 2021, 96, E210-E214.	2.0	7
98	The Role of Stromal Cells in Multiple Myeloma: Actors or Spectators?.. Blood, 2005, 106, 2506-2506.	0.6	7
99	Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection. Leukemia Research, 2005, 29, 159-163.	0.4	6
100	Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients. European Journal of Haematology, 2009, 82, 240-241.	1.1	6
101	The Impact of New Emerging Drugs in the Treatment of Multiple Myeloma:Is there Still a Role for PBSC Transplantation?. Current Stem Cell Research and Therapy, 2007, 2, 1-11.	0.6	5
102	A striking response to bortezomib in a patient with pleural localization of multiple myeloma. Leukemia Research, 2009, 33, 577-578.	0.4	5
103	Comparison of ibrutinib and idelalisib plus rituximab in realâ€life relapsed/resistant chronic lymphocytic leukemia cases. European Journal of Haematology, 2021, 106, 493-499.	1.1	5
104	Bisphosphonates and Osteonecrosis of the Jaw: Advantages of a New Schedule.. Blood, 2006, 108, 3590-3590.	0.6	5
105	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi. Frontiers in Oncology, 2021, 11, 789891.	1.3	5
106	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. Blood, 2014, 124, 150-150.	0.6	4
107	Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88^{WT}) WaldenstrÃ¶m macroglobulinemia (WM).. Journal of Clinical Oncology, 2020, 38, e20056-e20056.	0.8	4
108	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. Hematological Oncology, 2022, 40, 518-527.	0.8	4

#	Article	IF	Citations
109	Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. Leukemia Research, 2008, 32, 1085-1090.	0.4	3
110	Effectiveness of ibrutinib as firstâ€line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximabâ€bendamustine: Results of study on 486 cases outside clinical trials. American Journal of Hematology, 2021, 96, E269-E272.	2.0	3
111	Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study. Blood, 2021, 138, 134-134.	0.6	3
112	Use of BTK inhibitors with special focus on ibrutinib in WaldenstrÃ¶m macroglobulinemia: An expert panel opinion statement. Hematological Oncology, 2022, 40, 332-340.	0.8	3
113	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, , 1-4.	0.6	3
114	Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory WaldenstrÃƒÂ¶m Macroglobulinemia Patients. Blood, 2018, 132, 1607-1607.	0.6	2
115	Targeted Next Generation Sequencing Identifies Novel Genetic Mutations in Patients with Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma or IgM-Monoclonal Gammopathies of Undetermined Significance. Blood, 2016, 128, 2928-2928.	0.6	2
116	Ibrutinib for the Treatment of Bing-Neel Syndrome. Blood, 2018, 132, 1609-1609.	0.6	2
117	Treatment of Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). Blood, 2021, 138, 48-48.	0.6	2
118	First episode of acute hemolysis due to G6PD deficiency in a middle-aged woman and transmission of the enzymatic defect through bone marrow transplant. Haematologica, 2004, 89, ECR04.	1.7	2
119	Flexural erythematous eruption following autologous peripheral blood stem cell transplantation: a study of four cases. British Journal of Dermatology, 2001, 145, 490-495.	1.4	1
120	IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY. Hematological Oncology, 2019, 37, 183-184.	0.8	1
121	Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1643-1649.	0.9	1
122	Impact of Serum Immunoglobulin Subsets and Levels on Chronic Lymphocytic Leukemia Natural History: A Retrospective Multicentric Italian Experience. Blood, 2019, 134, 3026-3026.	0.6	1
123	Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires.. Blood, 2008, 112, 1775-1775.	0.6	1
124	Risk of Second Cancers in Waldenstrom Macroglobulinemia: a Population-Based Study From Northern Italy.. Blood, 2009, 114, 3951-3951.	0.6	1
125	The BRAF V600E Mutation in Hairy Cell Leukemia and Other Mature B-Cell Neoplasms. Blood, 2011, 118, 262-262.	0.6	1
126	High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents. Blood, 2013, 122, 1896-1896.	0.6	1

#	Article	IF	Citations
127	The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. Blood, 2015, 126, 1486-1486.	0.6	1
128	Results of a Phase II Multicenter Study of Immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Symptomatic Waldenstromâ€™s Macroglobulinemia. Blood, 2008, 112, 3692-3692.	0.6	1
129	Clinical and Biological Implications of Hepatitis C Virus Positivity in Waldenstrom's Macroglobulinemia Patients.. Blood, 2009, 114, 2934-2934.	0.6	1
130	Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenstroì¨m Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms.. Blood, 2012, 120, 2667-2667.	0.6	1
131	Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The â€œRete Ematologica Lombarda/Hematology Network Of Lombardia Regionâ€•. Blood, 2013, 122, 3003-3003.	0.6	1
132	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab. Blood, 2019, 134, 5485-5485.	0.6	1
133	Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE. Blood, 2019, 134, 5495-5495.	0.6	1
134	A revised international prognostic score system for WaldenstrÃ¶mâ€™s macroglobulinemia. Annals of Oncology, 2018, 29, viii359.	0.6	0
135	PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÃ–M MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY. Hematological Oncology, 2019, 37, 235-237.	0.8	0
136	Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN. Leukemia and Lymphoma, 2021, 62, 1782-1785.	0.6	0
137	Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting. Leukemia and Lymphoma, 2021, 62, 3311-3312.	0.6	0
138	Prognostic impact of somatic mutations on time to first treatment: Results of targeted nextâ€generation sequencing in 211 patients with early stage chronic lymphocytic leukemia. American Journal of Hematology, 2021, 96, E404-E408.	2.0	0
139	The Role of Whole-Body Magnetic Resonance Imaging in the Staging and Follow-Up of Bone Disease in Multiple Myeloma.. Blood, 2005, 106, 5063-5063.	0.6	0
140	Modification of Cytokine Levels and CD34+ Stem Cell Adhesion Molecules during Mobilization in Multiple Myeloma (MM) Patients.. Blood, 2005, 106, 5068-5068.	0.6	0
141	Has the Incidence of Extramedullary Disease Changed with the New Therapeutic Approaches? Analysis of a Cohort of 965 Multiple Myeloma (MM) Patients (pts).. Blood, 2007, 110, 4749-4749.	0.6	0
142	Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance: A Study on 1400 Cases. Blood, 2008, 112, 2706-2706.	0.6	0
143	Evaluation of the Impact of Three Different Pre-Transplant Strategies On the Outcome of Myeloma Patients Candidates to High-Dose Therapy.. Blood, 2009, 114, 1223-1223.	0.6	0
144	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. Blood, 2009, 114, 760-760.	0.6	0

#	Article	IF	Citations
145	Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS. Blood, 2010, 116, 3037-3037.	0.6	0
146	Immunoglobulin Heavy Chain (IGH) Gene Rearrangement In Waldenstroì^m Macroglobulinemia and Other Monoclonal IgM Disorders. Blood, 2010, 116, 4139-4139.	0.6	0
147	Clinical Significance of Tumor-Associated Macrophages in Early-Stage Hodgkin's Lymphoma.. Blood, 2012, 120, 2638-2638.	0.6	0
148	Hierarchical Clustering of B-Cell Receptor Structures in Splenic Marginal Zone Lymphoma. Blood, 2012, 120, 1585-1585.	0.6	0
149	Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS). Blood, 2012, 120, 3495-3495.	0.6	0
150	Bendamustine and Rituximab Combination Is Safe and Effective As Salvage Regimen in Waldenstrom's Macroglobulinemia. Blood, 2014, 124, 3072-3072.	0.6	0
151	Indolent Lymphomas: Follicular Lymphoma, HVC-Associated Marginal Zone B-Cell Lymphoma, and Waldenstromâ€™s Macroglobulinemia. , 2015, , 245-252.		0
152	Long Term Toxicity and Follow-up of WaldenstromÂ´s Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab. Blood, 2015, 126, 3958-3958.	0.6	0
153	Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. Blood, 2015, 126, 5084-5084.	0.6	0
154	WaldenstrÃ¶m Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study. Blood, 2019, 134, 1539-1539.	0.6	0
155	Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis. Blood, 2019, 134, 1502-1502.	0.6	0
156	External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study. Blood, 2019, 134, 4308-4308.	0.6	0
157	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. Blood, 2021, 138, 2641-2641.	0.6	0
158	High incidence of symptomatic cytomegalovirus infection in multiple myeloma patients undergoing autologous peripheral blood stm cell transplantation. Blood, 2000, 95, 4016-8.	0.6	0